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Abstract:  BACKGROUND: Psoriasis may signifi cantly impair sexual function. Depression and organic factors appear 
to play a key role in this relation. However, beyond genital psoriasis, the importance of the disease’s distribution 
patterns has not been considered. 
OBJECTIVES: To research sexual function in psoriasis patients and investigate the roles of anxiety, depression and 
psoriasis’ distribution patterns in sexual dysfunction. 
METHODS: A comparative study matched for sex and age was performed. Eighty patients with moderate to severe 
psoriasis and 80 healthy controls were included. The participants completed the Massachusetts General Hospital-
Sexual Functioning Questionnaire, the Hospital Anxiety and Depression Scale, and the Self-Administered Psoria-
sis Area and Severity Index. 
RESULTS: Psoriasis was associated with sexual dysfunction, odds ratio=5.5 (CI 95% 2.6-11.3; p<0.001). Certain distri-
bution patterns of psoriasis, involving specifi c body regions, were associated with an increase in sexual dysfunc-
tion in the group presenting the disease, odds ratio 7.9 (CI 95% 2.3-33.4; p<0.001). Multivariate logistic regression 
analysis identifi ed anxiety and depression, and the involvement of these specifi c areas, as possible independent 
risk factors for sexual dysfunction in patients with moderate to severe psoriasis. 
CONCLUSION: This study identifi es body areas potentially related to sexual dysfunction, independently of anxiety 
and depression, in psoriasis patients. The results suggest that the assessment of sexual dysfunction and the in-
volvement of these body areas should be considered as disease severity criteria when choosing the treatment for 
psoriasis patients.
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 INTRODUCTION
Psoriasis is a chronic, infl ammatory cutaneous 
disease with a worldwide estimated prevalence rang-
ing from 0.9 to 8.5 %. 1 Its impact upon patient’s quality 
of life is striking, with social and psychological conse-
quences comparable to those of other illnesses such as 
cancer, heart diseases or diabetes mellitus. 2,3 Psoriasis 
has been associated with different psychological prob-
lems, including low self-esteem, depression, anxiety, 
sexual dysfunction, or suicide ideation. 4-6 According 
to the World Health Organization (WHO), sexuality is 
a basic need and an element that cannot be separat-
ed from other aspects of human life, being extremely 
important for maintaining good mental health. 7 The 
impact of psoriasis upon sexual function seems to be 
substantial, and it can result in signifi cant alterations 
in quality of life. 8-11 The hypotheses proposed to ex-
plain such an increase in sexual dysfunction have tak-
en into consideration the severity of the disease, and 
psychological and physical comorbidities associated 
to psoriasis. 12 Psoriasis is correlated with marked stig-
matization regarding body image changes.6, 9 Howev-
er, with the exception of the genital area, we have not 
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found any studies on the impact of psoriatic lesions’ 
distribution patterns upon sexual function. The pres-
ent study evaluates and compares sexual function in 
patients with moderate to severe psoriasis versus a 
healthy population. Moreover, we have investigated 
the infl uence of depression or anxiety and psoriasis’ 
distribution patterns upon sexual function.
METHODS
Design and study population
A prospective case series study with patients 
diagnosed with moderate to severe psoriasis was con-
ducted between November 1st 2012 and February 1st 
2013. Severity was assessed according to a consensus 
document of the Spanish Academy of Dermatology. 13 
The study sample was recruited among the patients 
attending their scheduled follow-up visits to the 
psoriasis unit at the Granada University Hospital. A 
healthy volunteer, without the dermatological disease 
and matched for sex and age (±5 years) to each select-
ed psoriasis case, was recruited among those accom-
panying the dermatological and pediatric patients in 
the Dermatology and Pediatric clinics’ shared waiting 
room. The study was approved by the Ethic Commit-
tee of the Granada University Hospital.
Selection criteria were assessed through person-
al interview, and those who fulfi lled the criteria were 
invited to participate in the study. Inclusion criteria 
were: being 18 years of age or older and sexually ac-
tive. Exclusion criteria were: refusal to participate in 
the study, active dermatological diseases other than 
psoriasis, treatment with psychotropic drugs and oth-
er drugs well known to interfere with sexual function, 
intellectual disabilities, and active malignant diseas-
es. All participants gave written informed consent to 
participate in the study. The participants completed 
a self-administered questionnaire (identifi ed by code 
only). They fi lled it out by themselves in a quiet room. 
After completing the questionnaire, it was placed in a 
special container, and the participants could leave the 
hospital without seeing the medical staff again.
Main endpoints of interest and sources of in-
formation
Socio-demographic data and biometric param-
eters were collected through clinical interview and 
physical examination. Three physical comorbidities 
were considered in the analysis: hypertension, dys-
lipidemia, and diabetes mellitus. Diagnoses were ac-
knowledged when the patients received active treat-
ment for the disorders. In patients with psoriasis, 
severity was assessed calculating the body surface 
area affected by the disease (BSA), and using the Pso-
riasis Area and Severity Index (PASI). 14 PASI is ob-
tained by weighting the affected body surface area to 
the degree of desquamation, erythema and induration 
in different body regions. The following were consid-
ered as treatments: methotrexate, cyclosporine and 
acitretin categorized as classical systemic drugs; and 
infl iximab, etanercept, adalimumab and ustekinumab 
categorized as biological drugs.
The main variables were the presence of sex-
ual dysfunction, problems of anxiety and/or de-
pression, and psoriasis’ distribution patterns. The 
Massachusetts General Hospital-Sexual Functioning 
Questionnaire (MGH-SFQ) was used to assess sexu-
al function. 15 The MGH-SFQ is a self-administered 
questionnaire designed to detect sexual dysfunction, 
and has been validated in the Spanish population. 16 
The questionnaire comprises 5 items addressing the 
different phases of the sexual cycle: sexual interest, ex-
citation, orgasm, erection (only in males), and global 
sexual satisfaction. Each item is scored from 0 (com-
pletely reduced) to 4 (normal). High scores indicate 
better sexual functioning. Sexual dysfunction is con-
sidered when at least one item yields a score less than 
4. The prevalence of sexual dysfunction was estimated 
for psoriasis patients and healthy volunteers.
The Hospital Anxiety and Depression Scale 
(HADS) was used to evaluate the anxiety and de-
pression levels. 17 HADS is a self-administered ques-
tionnaire designed to assess anxiety and depression 
disorders, and has also been validated in the Spanish 
population. 18 The questionnaire consists of 14 items 
divided into two scales of 7 items each. A 4-point Likert 
scale, ranging from 0 to 3, evaluates the strength of 
the symptom. Subscale scores higher than 7 indicated 
signs of anxiety or depression, and scores higher than 
10 suggested a clinical problem. The prevalence of 
anxiety and depression was estimated by using these 
cut-offs. The human diagram of the Self Administered 
Psoriasis Area and Severity Index (SAPASI) was used 
to assess the distribution pattern of psoriatic lesions. 19 
Data from the diagram was coded into 22 body areas. 
Considering the prevalence of sexual dysfunction in 
the overall population – described subsequently– a 
sample with 80 psoriatic patients plus 80 healthy vol-
unteers would achieve a power higher than 80% to de-
tect differences equal to or higher than 20 points in the 
aforesaid prevalence between patients with psoriasis 
and the general population, with an alpha=0.05.
Data analysis
Descriptive statistics were used to explore the 
characteristics of the two groups, comparing those 
with psoriasis versus the control group. Continuous 
data were expressed as the mean and standard devi-
ation (SD). The absolute and relative frequency dis-
tributions were estimated for qualitative variables. 
MannWhitney Utest was performed to compare quan-
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titative data between psoriasis patients and healthy 
volunteers. The χ2 test or when necessary, the Fisher 
exact test were used for qualitative variables. Signifi -
cance was set at p<0.05. Crude and adjusted odds ra-
tios (OR), as well as confi dence intervals (CI 95%) were 
computed by logistic regression models, to explore 
factors associated with sexual dysfunction. The main 
outcome of interest, sexual dysfunction, was binary 
codifi ed as either sexual dysfunction (MGH-SFQ score 
less than 20 for males and less than 16 for females) or 
no sexual dysfunction (MGH-SFQ score = 20 for males 
and = 16 for females).16 Epidemiological and statistical 
criteria were used to model variable selection.20,21 The 
effect of each exploratory variable in the model and its 
signifi cance was studied. If the variable improved the 
model fi t and adequacy (based on the likelihood ratio 
criteria and the signifi cance of the parameter) it was 
kept; otherwise, the variable was excluded. Different 
models were fi tted with respect to the factors related 
to sexual dysfunction and psoriasis. The model was 
checked for pair-wise interaction between covariates. 
Interactions with sex and age were considered. Poten-
tial confounding covariates were studied using a sig-
nifi cance change of the parameters in the model or a 
change of 30% of its value.22 Once the model was fi tted 
to the data, the adequacy of fi t was assessed by the 
Hosmer-Lemeshow test. A sub-analysis was conduct-
ed to explore the impact of psoriasis’ distribution pat-
terns on sexual function in patients with the disease. 
Analyses were performed using the Stata statistical 
software (version 11.0).
RESULTS
A total of 95 patients with moderate to severe 
psoriasis were invited to join the study. Four of these 
patients had intellectual disabilities, and were thus 
excluded. Five patients undergoing treatment for de-
pression and one patient with psychotic disorder were 
also excluded. Five patients decided not to participate, 
citing lack of time to complete the questionnaire. In 
turn, 88 healthy controls matched for age and sex were 
invited to participate. Two controls were in treatment 
for depression and were excluded. Six of the controls 
decided not to participate, citing a lack of time. The 
study was therefore carried out on 80 psoriasis pa-
tients and 80 healthy controls. Table 1 summarizes 
the socio-demographic characteristics of those partic-
ipating in the study. Both groups were comparable in 
terms of age, sex, educational level, marital status and 
occupation. Table 2 shows the clinical features of pa-
tients with psoriasis.
The results of the MGH-SFQ are summarized 
in table 3. Compared to controls, the psoriasis group 
showed signifi cant impairment of all the components 
of sexual function. “Sexual interest” and “global sex-
ual satisfaction” were the most negatively affected 
components. Male patients with psoriasis showed an 
increase in erectile dysfunction compared to controls. 
The prevalence of sexual dysfunction was 53.7% in 
patients with psoriasis vs. 17.5% in healthy volunteers 
(p<0.001). The frequency of sexual dysfunction, in the 
crude analysis, was higher in psoriasis patients com-
pared to controls, 5.5 (CI 95% 2.6-11.3; p<0.001). A sub 
TABLE 1: Socio-demographic characteristics of the participants. (Granada University Hospital, 2012-2013)
 Healthy volunteer Psoriasis (n=80) p-values
 (n=80)  
Age (years) 41.0±13.1 43.4±12.7 0.225
Male: female ratio 1:1 1:1 1.000
Marital status (%)   0.675
Single 20 (25.0) 18 (22.5) 
Married 58 (72.5) 58 (72.5) 
Other 2 (2.5) 4 (4.9) 
Educational level (%)   0.797
Primary incomplete 26 (32.5) 30 (37.5) 
Secondary 21 (26.3) 20 (25) 
Academic 33 (41.2) 30 (37.5) 
Employment status (%)   0.341
Employed 46 (57.5) 40 (50.0) 
Unemployed 34 (42.5) 40 (50.0) 
Place of residence (%)   0.409
Urban 54 (67.5) 49 (61.2) 
Rural 26 (32.5) 31 (38.8) 
BMI 24.1±3.2 28.2±6.7 <0.001*
Smoking 4 (4.9) 26 (32.5) <0.001*
Arterial hypertension 10 (12.5) 19 (23.7) 0.065
Dyslipidemia 3 (3.7) 9 (11.2) 0.071
Diabetes mellitus 1 (1.2) 5 (6.2) 0.096
Data are expressed as mean ± standard deviation and as number (percentage) BMI: body mass index. * p-values < 0.05 were considered statistically signifi cant
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analysis including drugs for psoriasis treatment was 
performed. No association between drugs for psoria-
sis treatment and sexual dysfunction was found.
The results of the HADS are shown in table 3. 
The frequency of anxiety signs, considering a cut-off 
score above 7, was higher in patients with psoriasis 
than in the overall population, 50% vs. 20% respective-
ly, OR 4.0 (CI 95% 1.9 – 8.0; p<0.001). The same was 
observed for signs of depression. Although the abso-
lute magnitude was lower than that of anxiety, 32.5% 
vs. 4.9% for psoriasis patients and healthy volunteers 
respectively, the relative magnitude of the association 
was higher, OR 9.1 (CI 95% 3.0 – 27.7; p<0.001). Since 
nearly all the subjects with signs of depression also 
presented signs of anxiety, a new variable, “signs/ev-
idence of anxiety and/or depression”, which included 
all the subjects with a cut-off score higher than 7 on the 
HADS anxiety subscale or HADS depression subscale, 
was coded. Therefore, there seemed to be a co-relation 
between psoriasis, signs of anxiety and/or depression 
and sexual dysfunction. Table 4 shows the factors asso-
ciated with sexual dysfunction. After adjusting for signs 
of anxiety and/or depression, the observed association 
between psoriasis and sexual dysfunction remained 
signifi cant, adjusted OR 2.9 (CI 95% 1.2– 7.0; p=0.016)
After coding the results of the SAPASI body 
diagram in the psoriasis group, the ventral regions of 
legs/shins were found to be the most frequently af-
fected body area (56.2%), and 18.7% of the patients 
showed involvement of the genital area. The associa-
tion between the different body areas and sexual dys-
function is summarized in table 5. Psoriasis lesions on 
the genitals, buttocks, abdomen or lumbar region were 
signifi cantly linked to sexual dysfunction. A new vari-
able, which included all patients with psoriasis lesions 
in any of these Areas of Sexual Impact (ASI), was cod-
ed. Figure 1 represents the distribution and frequency 
of lesions in psoriasis patients with sexual dysfunc-
tion. Psoriasis patients with ASI involvement showed 
a 7.9-fold higher risk of developing sexual dysfunction 
than psoriasis patients without it  - adjusted OR 7.9 (CI 
95% 2.3 – 33.4; p<0.001). Finally a sub-analysis includ-
ing only the patients without ASI involvement was 
conducted. The results showed that psoriasis patients 
without ASI involvement did not have a greater risk of 
sexual dysfunction than controls, adjusted OR 1.1 (CI 
95% 0.3 – 3.8; p=0.873).
TABLE 3: Results of the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) and of 
the Hospital Anxiety and Depression Scale (HADS). (Granada University Hospital, 2012-2013)
TABLE 2: Characteristics of psoriasis patients. 
(Granada University Hospital, 2012-2013)
MGH-SFQ Controls Psoriasis p-values
Sexual interest 3.7±0.8 2.9±1.4 <0.001
Sexual arousal 3.8±0.8 3.0±1.3 <0.001
Orgasm 3.7±0.8 3.1±1.3 <0.001
Erection (only male) 3.9±0.2 3.2±1.1 <0.001
Global sexual satisfaction 3.6±0.9 2.9±1.4 <0.001
Total score male 19.3±3.2 16.2±5.3 0.002
Total score female 14.6±3.9 11.2±5.6 0.002
Individuals with sexual dysfunction (%) 14 (17.5) 43 (53.7) <0.001
HADS Controls Psoriasis p-values
Signs of anxiety (HADS-A 8≤) 16 (20.0) 40 (50.0) <0.001
Signs of depression (HADS-D 8≤) 4 (4.9) 26 (32.5) <0.001
Signs of anxiety and/or depression 17 (21.5) 43 (53.7) <0.001




Nail involvement 31 (38.7)
Psoriatic arthritis 24 (30)
Age at onset 22 (13~38)
Years of evolution 9 (3~27)
Psoriasis treatment 
Topical 14 (17.5)
Classical systemic drugs 27 (33.7)
Biologic drugs 39 (48.7)
Data are expressed as mean ± standard deviation and as percentage (number). MGH-SFQ: Each item is scored from 0 (completely reduced) to 4 (normal). Sexual 
dysfunction: score less than 20 for males and less than 16 for females. HADS-A: anxiety subscale. HADS-D: depression subscale.
Data are expressed as median (percentile 25~percentile 75) and as number 
(percentage). BSA: body surface area affected by psoriasis. PASI: Psoriasis 
Area and Severity Index.
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DISCUSSION
To our knowledge, this is the largest prospec-
tive analytical study on sexual dysfunction in patients 
with moderate to severe psoriasis using a validated 
and specifi c measurement tool to assess sexual func-
tion, and the fi rst to broadly explore the impact of pso-
riatic lesions’ distribution patterns on sexual function. 
The results of our study show a meaningful clinical 
association between moderate to severe psoriasis and 
sexual dysfunction. The human sexual response cycle 
is complex. Certain components of sexual response, 
such as sexual interest, depend primarily on psycho-
logical factors, and are impaired by conditions such as 
anxiety and depression, while others such as erection 
and orgasm can be affected by psychological and phys-
ical causes.23,24 Sexual impairment in psoriasis patients 
occurs in all components of the sexual response. This 
suggests that sexual dysfunction in psoriasis must be 
a consequence of several combined factors.
TABLE 4: Univariate and multivariate logistic regression analysis of potential factors linked to sexual dysfunction. 
(Granada University Hospital, 2012-2013)
TABLE 5: Psoriatic lesions’ distribution patterns and associated sexual dysfunction. 
(Granada University Hospital, 2012-2013)
 Univariate analysis p-value Multivariate analysis p-value
 Unadjusted OR  Adjusted OR 
Psoriasis 5.5 (2.6-11.3) <0.001* 2.9 (1.2-7.0) 0.016*
Age 1.0 (0.9-1.1) 0.609 1.0 (0.9-1.1) 0.992
Sex 0.5 (0.3-1.1) 0.069 0.5 (0.2-1.1) 0.080
BMI>25 kg/m2 1.7 (0.9-3.4) 0.095 0.9 (0.4-2.2) 0.823
Smoking 6.1 (2.5-14.6) <0.001* 5.0 (1.8-15.0) 0.001*
Arterial hypertension 3.7 (1.6-8.8) 0.002* 5.4 (1.8-17.2) 0.002*
Dyslipidemia 2.6 (0.8-9.3) 0.096 2.8 (0.4-18.4) 0.228
Diabetes mellitus 1.8 (0.3-10.3) 0.463 0.3 (0.1-3.4) 0.379
Signs of anxiety and/or depression 3.9 (1.9-7.7) <0.001* 3.5 (1.5-8.2) 0.003*
 Subjects with Sexual dysfunction with Sexual dysfunction without p-values
 lesions on these areas lesions on these areas lesions on these areas
Face 10 (12.5) 5 (50.0) 38 (54.2) 0.065
Chest 25 (31.2) 16 (64.0) 27 (49.0) 0.215
Abdomen 34 (42.5) 23 (67.6) 20 (43.4) 0.032*
Genitals 15 (18.7) 13 (86.6) 30 (46.1) 0.002*
Arms 14 (17.5) 10 (71.3) 33 (50.0) 0.144
Forearms (ventral surface) 25 (31.2) 14 (56.0) 29 (52.7) 0.785
Palms 14 (17.5) 9 (64.2) 34 (51.5) 0.384
Thighs 23 (28.7) 16 (69.5) 27 (47.3) 0.071
Knees 27 (33.7) 16 (59.2) 27 (50.9) 0.480
Shins/Legs 45 (56.2) 23 (51.1) 20 (57.1) 0.591
Foot (dorsal surface) 12 (15.0) 8 (66.6) 35 (51.4) 0.330
Scalp 34 (42.5) 21(61.7) 22 (47.8) 0.216
Dorsal region 18 (22.5) 11 (61.1) 32 (51.6) 0.467
Lumbar region 31 (38.7) 21 (67.7) 22 (44.9) 0.046*
Arms (dorsal surface) 14 (17.5) 10 (71.4) 33 (50.0) 0.144
Elbow 41 (51.2) 24 (58.5) 19 (48.7) 0.378
Forearm (dorsal surface) 21 (26.5) 13 (61.9) 30 (50.8) 0.383
Hand (dorsal surface) 15 (18.9) 9 (60.0) 34 (53.1) 0.592
Buttocks 29 (36.2) 22 (75.8) 21 (41.1) 0.002*
Femoral region 28 (35.0) 18 (64.2) 25 (48.0) 0.165
Soleus region 34 (42.5) 19 (55.8) 24 (52.1) 0.742
Sole of the foot 10 (12.5) 8 (80.0) 35 (50.0) 0.075
ASI 35 (56.2) 31 (68.8) 12 (34.2) 0.001*
* p-values < 0.05 were considered statistically signifi cant. BMI: body mass index. Adjustment variables: psoriasis, sex, BMI > 25 kg/m2, smoking, arterial hyper-
tension, dyslipidemia, diabetes mellitus, signs of anxiety and/or depression.
* P-values < 0.05 were considered statistically signifi cant. ASI: Areas of Sexual Interest
 An Bras Dermatol. 2015;90(3):338-45.
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 Few studies have been published in the fi eld of 
sexual dysfunction in psoriasis and its possible caus-
es.12 The main causal hypotheses have focused on the 
role of psychological morbidities. All the studies that 
evaluated psychological factors have proposed de-
pression as a key link between psoriasis and sexual 
dysfunction.10,25-27 The prevalence of sexual dysfunc-
tion in psoriasis patients in our study coincides with 
previous reports.9, 12, 27 In agreement with prior studies, 
we observed that depression is likely of great impor-
tance in the causal relationship between psoriasis and 
sexual dysfunction, because of its increased preva-
lence in this population. Consistent with the available 
scientifi c evidence, psoriasis patients with signs of de-
pression had a higher risk of sexual dysfunction com-
pared with psoriatic patients without such problems12. 
In our study we have considered anxiety, which is also 
connected to sexual dysfunction and psoriasis, and 
have chosen a low cut-off score for anxiety and de-
pression in the analysis in order to include all subjects 
with psychological impairment and comprehensively 
characterize the role of a psychological linking factor 
between psoriasis and sexual dysfunction.28,29 How-
ever, even after expanding the range of psychological 
conditions and performing an adjusted analysis, the 
association between psoriasis and sexual dysfunction 
remained clinically and statistically signifi cant. Con-
sequently, the aforementioned factor would not be the 
only element implied in this relationship.
Furthermore, psoriasis itself may play an im-
portant role on sexual dysfunction development in 
these patients. In this sense, patients with involvement 
of ASI areas, frequently affected by psoriasis and co-re-
lated with important stigmatization, are more likely to 
suffer sexual dysfunction than patients that are free 
of lesions in these areas30,31 fi gure 1. This association 
was independent of anxiety or depression levels, and 
these areas were thus referred to areas of sexual im-
pact (ASI). Physiological and pathological changes in 
body image, such as pregnancy or surgical sequelae, 
have been linked to sexual dysfunction through the 
impairment of self-esteem and sexual distress.32-34 Un-
expectedly, studies that offer an in-depth analysis on 
the repercussion of body image changes in dermato-
logical diseases and their impact on sexual function 
are scarce - particularly considering that changes in 
body image are virtually constant in cutaneous dis-
eases.7, 9, 35 Psoriasis implies obvious changes in body 
image in the form of visible and touchable lesions that 
can affect any corporal area. Psoriasis lesions can af-
fect visible body regions, and the involvement of such 
areas has been linked to greatly impaired quality of 
life and prominent interference in social relationships. 
Such lesions are therefore regarded as severity crite-
ria in deciding the therapeutic approach.13,36,37 Sexual 
dysfunction secondary to psoriasis affecting ASI could 
probably be facilitated by feelings of stigmatization, 
shame, low self-esteem and increased sexual dis-
tress.38-40 These feelings would arise specifi cally during 
sexual activity, and consequently sexual dysfunction 
linked to ASI involvement is independent of the psy-
chological state in terms of anxiety or depression. 
We conducted a sub-analysis including only patients 
without ASI involvement, which showed sexual func-
tion to be similar to that of the control group when 
ASI areas were not affected by psoriasis lesions. Thus, 
the presence of signs of anxiety and/or depression 
and ASI involvement could be considered as possible 
risk factors in the link between psoriasis and sexual 
dysfunction.
We acknowledge some methodological weak-
ness in our study: 1) The cross-sectional character of 
the study. We have included prevalent cases of psori-
asis in the analyses and, therefore, we cannot confi rm 
the causality hypothesis. However, the magnitude of 
the found associations is very strong and we should 
consider the potential role of the psoriasis itself on sex-
ual dysfunction occurring in affected patients; 2) Sam-
FIGURE  1: Tridimensional parametric representation of areas of 
sexual interest (ASI). The amount of lesions in the body diagram 
represents the proportion of psoriasis patients with involvement 
of these areas, which have sexual dysfunction. ASI areas appear 
highlighted in red. *Odds ratio between the involvement of each 
ASI component (abdomen, genitals, buttocks and lumbar area) and 
sexual dysfunction
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ple selection was not random, and the controls were 
healthy volunteers, thus raising the possibility of selec-
tion bias. Nevertheless, we matched them by age and 
sex to try and avoid a possible bias of control group. 
In fact, the frequency of sexual dysfunction in the pso-
riasis group is so high that the results could scarcely 
be explained by bias; 3) The study’s sample size was 
limited, although it was suffi cient to achieve a power 
higher than 80%. So, the causal inferences should be 
viewed with caution due to the study design. A larger 
study with incident cases of psoriasis should be per-
formed to comprehensively explore causality. Future 
research in the fi eld of psoriasis and sexual dysfunc-
tion should investigate the linking factors between 
ASI lesions and sexual dysfunction, and which are the 
causes of dysfunction amongst the different compo-
nents of the sexual response cycle. In addition, studies 
considering biological markers of systemic infl amma-
tion or imaging techniques such as dynamic penile 
color-duplex ultrasound are warranted.
CONCLUSION
In conclusion, we have found a high frequency 
of sexual dysfunction problems in psoriasis patients, 
and we have identifi ed two potential independent fac-
tors involved in this relation: anxiety and/or depres-
sion and ASI lesions. We suggest that the assessment 
of sexual function should be a part of the comprehen-
sive care of moderate to severe psoriasis patients. For 
this purpose, the MGH-SFQ is a useful and simple 
tool to be used in daily clinical practice. Screening 
and treatment of anxiety and depression, which are 
quite prevalent in this group of patients, should also 
be considered because clinical signs of these condi-
tions can signifi cantly impair sexual function. During 
physical examination, special attention should be paid 
to ASI involvement, which could be considered as a 
severity criterion in deciding treatment, since this in-
volvement signifi cantly and independently impairs 
sexual function.❑
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